Telomerase Reverse Transcriptase Gene Transfection of Human Amniotic Electrical Mesenchymal Stem Cell Transplantation for Treatment of Diabetes Mellitus
Total Page:16
File Type:pdf, Size:1020Kb
ęඈඋ1࣏ۘऺ ৰ 19 Ż ৰ 36 ƛ 20150903 ϦČ Chinese Journal of Tissue Engineering Research September 3, 2015 Vol.19, No.36 www.CRTER.org ୖ›ǑḰơ›ȖüϹḰɏ¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉ͏ћசɳ҉ Äņᇽ(ǧSďS˂ˡŋʒ½ˍãKǧSď 300350) তͥ fK˿K1983 ˝ÛK ĚȈ࿁3Ⴎu̩:࿁ṇƆĽͥ «ֲQ¾ඊྡྷϣۘऺ:ǻₑᡅՈඊྡྷࢿΉ ȩ ၠⒸ̱ᯬ¾ඊྡྷͣƅ̶๎ ǡļ7P4তȘᜬ Ởẋୖ›ǑḰơ›ȖüϹḰɏ¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉdzƅά͏ћசɳ҉4 ̂ZàǁďNK˩ȂK 2010 ˝ 7 ÅǧSãî ͟⏲᪑ ϤKœþKå ۔ඊྡྷࢿΉ¦๎ၠⒸ̱ᯬ¾ඊྡྷசɳ҉ाွᜄசྴˏୖ›ǑḰơ›Ȗüᜄச֕ϟ̓¾ 'L᪑ ȁ·ȔŀYȩ fKǧS ¾ඊྡྷඈඋ1࣏ᜄசசɳ҉ ď S ˂ ˡ ŋ ʒ ½ ˍ ෭Щ᪱ ãKǧSď 300350 ୖ›ǑḰơ›human telomerase reverse transcriptase hTERT Ě ିǻ:R394.2 B:ۅDzʃ ʼᡅ তේǻ:2095-4344 ྐë๎ၠ«ྒ̫ϦϣȒՈëŏĭ ๎ၠⒸ̱ᯬ¾ඊྡྷͣƅǚnj5ƫ3ʺȪ࿁Ɔ3\Ēˊƚuᩲ3̹ѯƣ (2015)36-05827-06 ɳĺĄÃ4 ɘ4ěY2015-07-25 ՈỞẋୖ›ǑḰơ›(human telomerase reverse transcriptase hTERT)ȖüϹḰɏ¦๎ၠⒸ̱ᯬ¾ඊ http://WWW.crter.orgֲ Ոћά4۔சɳ҉µƧ Ȇᩬ͢ȭசɳ҉̓۔ࢿΉ4̓ྡྷ ƶǚ╓۔̓ ࡿȕͧ¦๎ၠⒸ̱ᯬ¾ඊྡྷ ඓ hTERT ȖüϹḰɏ๎ၠⒸ̱ᯬ¾ඊྡྷ º 50 Ǯ SD 5ͩ 10 Ǯň&ȭ+ඈ mŅ 40 Ǯŭ 45 mg/kg ՈFₓͼȸ⏂◍ ņএசɳ҉µƧȒ Ⱥņµt£Ո 36 Ǯ SD &சɳ҉ඈ3¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈʐ hTERT¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈ ɣඈȈ 12 Ǯ ƶ╓۔̓ ა[☝ͼȸࢿΉ¦๎ၠⒸ۔/Ởẋ̓ ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈʐ hTERT¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈ๎¦ ᯬ¾ඊྡྷʐඓ hTERT ȖüϹḰɏ๎ၠⒸ̱ᯬ¾ඊྡྷ4ࢿΉȒȈඈẟᜐ¬ɍᜄசˈ¿֕ϟ zࢿΉȒɣɬ̼̱ ċᆓƤஂö൦ɏᄶᢆȓ҉ˊǜĚ4 ᜄϚྴˏՈϧò ྴှ۔ϟȈඈ̓ Ș^ࢿΉȒ 4 ɬ ^சɳ҉ඈɨṇ ¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈʐ hTERT¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿ Ήඈᜄசˈ¿º[┑(P < 0.05) ɘ͢« hTERT¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈՈाွᜄசˈ¿ȉẕzȭ+ඈ ˈ¿(P > 0.05) ໐சɳ҉ඈाွᜄசමťńṇʌˈ¿ࢿΉȒ 6 ɬ ^சɳ҉ඈɨṇ ¦๎ၠⒸ̱ᯬ¾ඊྡྷ ࢿΉඈʐ hTERT¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈՈᜄϚྴˏȯₓʺ¤(P < 0.05) ྴှ҉ǃ࣏òλḿ(P < 0.05) hTERT¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈŰº(P < 0.05)4Ș᪅ǒ ȴ߾ hTERT ḰɏՈ๎ၠⒸ̱ᯬ¾ சɳ҉4۔ᜄசʐλḿྴˏǃĐ dzÑƅά͏ћ̓۔ඊྡྷࢿΉ࿁º┑ĺசɳ҉̓ :(Äņᇽ. ୖ›ǑḰơ›ȖüϹḰɏ¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉ͏ћசɳ҉[J].ęඈඋ1࣏ۘऺ 2015 19(36 5827-5832. doi:10.3969/j.issn.2095-4344.2015.36.016 Telomerase reverse transcriptase gene transfection of human amniotic electrical mesenchymal stem cell transplantation for treatment of diabetes mellitus Fu Jian-ru (Department of Internal Medicine, Xianshuigu Hospital of Jinnan District, Tianjin 300350, China) Abstract BACKGROUND: The amniotic membrane is the rejected material after birth. Amniotic mesenchymal stem cells are characterized as easy harvesting, strong proliferation ability, no ethical controversy, and low immunogenicity. OBJECTIVE: To electrotransfer human telomerase reverse transcriptase (hTERT) gene into amniotic mesenchymal stem cells transplanted into diabetic rats and to explore its effect on diabetic rats. Fu Jian-ru, Master, Physician, METHODS: Human amniotic mesenchymal stem cells were isolated, cultured and electrotransferred by hTERT Department of Internal gene. Ten of 50 Sprague-Dawley rats were randomized selected as controls, and the remaining rats were used to Medicine, Xianshuigu Hospital establish diabetic models through injection of 45 mg/kg streptozotocin. Thirty-six model rats were randomized into of Jinnan District, Tianjin model group, cell transplantation group and hTERT-transfected cell transplantation group, with 12 rats in each 300350, China group. In the latter two groups, human amniotic mesenchymal stem cells and hTERT-transfected amniotic Corresponding author: Fu mesenchymal stem cells were injected via sublingual veins, respectively. After transplantation, blood glucose Jian-ru, Department of Internal levels were monitored dynamically, and plasma insulin concentration was detected every week. Pancreas tissues Medicine, Xianshuigu Hospital were taken and cut into sections for histological observation using hematoxylin-eosin staining. of Jinnan District, Tianjin RESULTS AND CONCLUSION: At 4 weeks after transplantation, the blood glucose levels were significantly lower in 300350, China the two cell transplantation groups than the model group (P < 0.05), and especially in the hTERT-transfected cell transplantation group, the blood glucose level was close to the normal value (P > 0.05). However, the model group still Accepted: 2015-07-25 ISSN 2095-4344 CN 21-1581/R CODEN: ZLKHAH 5827 Äņᇽ. ୖ›ǑḰơ›ȖüϹḰɏ¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉ͏ћசɳ҉ www.CRTER.org had a higher blood glucose level. At 6 weeks after transplantation, compared with the model group, the plasma insulin concentration was significantly increased in the two cell transplantation group (P < 0.05), and the severity of pancreatic injury was also eased in these two groups (P < 0.05), especially in the hTERT-transfected cell transplantation group (P < 0.05). These findings indicate that hTERT-transfected amniotic mesenchymal stem cell transplantation can dramatically decrease blood glucose level and relieve pancreatic injury in diabetic rats, which is an effective method for treatment of mellitus diabetes in rats. Subject headings: Stem Cells; Tissue Engineering; Blood Glucose; Diabetes Mellitus Fu JR. Telomerase reverse transcriptase gene transfection of human amniotic electrical mesenchymal stem cell transplantation for treatment of diabetes mellitus. Zhongguo Zuzhi Gongcheng Yanjiu. 2015;19(36):5827-5832. 50Ǯ Ŀᯬₓ۔šᣄ Introduction 1.3.1 ǒɀ¬ĭ ɑă1Ƅܸ▐ɳSD̓ 0 ϣĿƚՈẉợǕʉ -Ϭ¾ඊྡྷՈϣ£࿁ǡ 210Û225 g ᯱႮęĿƚƚ┦¬ĭǒɀǘ ¬ĭᯬₓ╓ ŻÏ¦Ŀ͍£࿁Ոnjʐඈඋ ǡẂ4͏ћֲՈՈּ͟ Ȍʸ᪅ǻSCXK(ι)200500024 ऺᱎǡᱎ̶[1-3]4ü¾ඊྡྷͣƅʌòႮuŰ,࿁ʐ̶ȕ 1.3.2 ๎ၠ ¦๎ၠǡႮͅιNιśľʼˈ͑Ŀ┦Ոۘ ĚȈ࿁ ᝯň&ඊྡྷ͏ћʐȖü͏ћՈˊ̿☺ඊྡྷ4 Σ ºᱷƄZǟ,ѐྒ֜iࡿ๎ၠ4ΣQ̼ɡEཡ ¦๎ၠⒸ̱ᯬ¾ඊྡྷ«ºྒ̫ ]ȒՈëŏĭ๎ၠ ҉ɦ3ཡ҉ɦ3́ɦᙾGĿʐ¦ି̹ѯ┻҉ɦţ&⓸ Ȑ͛R4̑کȐ͛ Âੂึ̑کȴǚϦ ͢Ĺzྒ֜Ոżͱɶ ϵZղɶ3ȖၠɶʐⒸᯬ ɳ4ǒɀQඓẋΣඓ ɶ3ɶȀඈt \ཐཌྷ3ࠢඓ3ᜄÑǎw@ிඣ ɨṇ 1.4 ôκǒƽ ࡿ[4-6]4¦๎ၠⒸ̱ᯬ¾ඊྡྷ'ᡅǡļz๎ 1.4.1 ¦๎ၠⒸ̱ᯬ¾ඊྡྷՈȕͧǎℸǎ ቻǚྒ֜w ǭ^ඖɯၠ ๎¦ࡿቻǚ Ȑ͛ ƉǒdžDz[16]Ո5ͩ̑کĚȈ࿁[7-8]4ୖ› ̴ǣ4 ၠՈྞɶ ۘऺǕɴ͢Kͣƅ̶ȕ ^ڃǑ Ḱ ơ › (human telomerase reverse transcriptase ၠ4₋ϬD-Hank’s^Ǒ̩ΫP๎ၠѱ┨ȟНᜄ¹3 ϔ0.25%Ոྴ› 37 ?[200 r/min ĚՈŊọϣ⑃üƄ7P ͣƅ nݒ๎ၠ าĿࢳ hTERT)«᫇ȋʺȪǎǎȕ ̶ₑϣĭƚάà[9-10]4 4Ě10 minȒ±┨¦๎ၠZղඊྡྷ ŏƿ4Ě^ ඓ̝l ϔ0.01%Ո rⒸͱٰⒸǀt ř Ȓʇ͑,ѐ4Ě^ ₑ̩ẟᜐ2ƵȒ4ϬĿࢳڱϹḰɏ̱ͩňř dzÑń ƵdzÑ̓ÝₓḰɏ «·ȰȖüḰȰՈϬ5ͩ[11]4╓ ྺƣ›ǎDNA›£Ȍ^ń37 ?[Ñ200 r/minණනGḰ4 ¦ØϣϏˈ¿Ոȴʌ சɳ҉ՈǕ҉ɋńАȈŌţº߾ Ě1 h4Ǒ4Ěඈඋtలź -Ϭ]⏌⍦ตẋƐȒ Ⱥඊྡྷ Ϧͤŋᱏà ȭ¦ିɑăźΡǛ4ₑƽˑ[12-13]4ǒɀȆ ˸^Κ▊ ȯĿࢳ ϔ10%FBSՈDMEMȕͧ^ₑ,̝l Ȓ ˸ඊྡྷ ẟᜐඊྡྷᩥϔ z25 cm2ȕͧκͱ าz37 ?3۔ᩬhTERTᜬẂՈ๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉ͑சɳ҉̓ ȭசɳ҉͏ћՈάȘ4 Ŀࢳ ϔ5%CO2ĥʐīòȕͧੵȕྲྀ ȕͧ40 hȒŰdž ^Ŀ ŏƿƦ˝ඊྡྷ Âᢆȓ4˝ඊྡྷ☦ࢳẂ90%r 1njʐ5ͩMaterials and methods ỞẋĿࢳ ϔ0.25%Ոྴ›4Ěඊྡྷ ࡿȏȒቻǣ¦๎ၠ 1.1 Éα ╓ƶȭ+¬ĭǒɀ4 Ⓒ̱ᯬඊྡྷ4ǾาºǺ␠[ᢆȓඊྡྷƮɍ4ǚP3Ïඊྡྷ 1.2 ðϏΛıļ z2014À2ƄႷ2015À1ƄńͅιĿ ŭϕśඊྡྷÖ᪙F᪸Rẟᜐ̱ň 4ĚȒ¤͑PE FITC ̓ƚȏǒɀǘǀt4 ʃᩴՈCD9 CD13 CD19 CD29 CD34 CD44 CD45 1.3 ƨ CD46 CD49ûĿẟᜐඊྡྷՈϕśඊྡྷÖℸǎ4 1.4.2 hTERTϹḰɏ๎ၠⒸ̱ᯬ¾ඊྡྷ ๎ၠⒸ̱ᯬ¾ ୖ›ǑḰơ›ȖüϹḰɏ¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉ͏ћசɳ҉ǒɀ'ᡅ ඊྡྷń37 ?3Ŀࢳ ϔ5%CO ǝâ[ᢈȕͧ24 h4Ⱥ̠ ᪙FǎÖ 2 zȭϔϣ⑃ƛՈඊྡྷ :třඊྡྷ˸^ PBS±ΫÂඓྴ› ᪙FǎÖ ǡļ 4ĚȒ ࡿȏΚ▊๎ၠⒸ̱ᯬ¾ඊྡྷ ϬϹृƈΞ^ₑ Ƀğᜄ± ๒ęBecon Dickinson͘Ǽ ˸ ࡿȏ800×g ☝า5 min ±Ϋඊྡྷ3Ƶ ࡿȏ ₑ˸ ྒğᜄ±3DMEMȕͧ^Ŀࢳ ϔ0.25%ྴ ๒ęGibco͘Ǽ zϹḰ^ ḰࢿาϹϧǫ ¤͑20 µgՈᯬୖDNA £Ą ›3BƧྺƣ›3⏂ነ าΜZ30 minȒ ÑϹƏ350 V/cm Ϲǭ25 µF rⒸ β-actin̶̷ ๒ęBD͘Ǽ۔û¦hTERT̶̷╊ûĿ3̀û̀ MBPûĿ ϔT&0.9 msՈϹḰĚdžϔ ẟᜐϹृƈ4ȺḰɏȒՈ۔ûĿ ʐ̀û╊ ୖ› ǑḰơ› ̓ẢǑϣϣĭ͘Ǽ hTERT๎ၠⒸ̱ᯬ¾ඊྡྷาzǘÕ30 min ඊྡྷࢿ͑ DMEMȕͧȖ ȯĿࢳ ϔ10%Ƀğᜄ±ǎ1%ǐûՈȕͧ mRNAȴǚ᪙F֖3PCRǑà᪙F֖ ๒ęKPL͘Ǽ փ าz37 ?3Ŀࢳ ϔ5%CO2Ʃੵͱȕྲྀ4 (#ELISA᪙F֖ Excell(ęZˏྴ ඈ Ⴎ50Ǯɑă▐ɳSD µƧ:̣ǎ۔சɳ҉̓ 1.4.3 AMVǑḰơ᪙F֖ ěͅʵϣĚƅ└͘Ǽ ŭ╓ƶͩǚ10Ǯň&Ƿȭ+ඈ ඝtĿࢳFₓP۔̓ ᜄசϟǎÖ Eukare ǴĪ̬Ī͘Ǽ ࡅ12 h Â۔ƵɳͼȸՈϣˊ֔ˈ4ȺŅ[Ո40ǮSD̓ 5828 P.O. Box 10002, Shenyang 110180 www.CRTER.org Äņᇽ. ୖ›ǑḰơ›ȖüϹḰɏ¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉ͏ћசɳ҉ www.CRTER.org zა[☝ͼȸ45 mg/kgFₓՈ⏂◍(ϬQŢzpH ⒸϔǒɨṇϬʳƨt ̼ɀ ̼ɀˈβα=0.054 4.5Ոɜŀ‼֔Ξ^) 1ɬͱẢන2Ƶ3Ⓒ╘ႷɅ2 d Ƨ ƵͼȸȒ zɣɬǚɲ☝ᜄச1Ƶ ᜄச֕ϟẢන3Ƶ̓ 2ȘResults &50Ǯ ╓ƶǚ10Ǯň۔z16.7 mmol/L ໐/Ϧɴ̶3̶Ģ3̶ɳ3ĿᯬₓλɅ 2.1 ôκŦʦļƘǫʭ ൷͑̓ ȭ+ඈ 36Ǯdž^Ụµ ȏʐͫɏ4ǮX┨ żඌᩥ͑ ۔Ụµt£4Ụµẋ࣏ 3Ǯ¬ĭȏ 1ǮƌϏՈ̓& ᜄசϧò]ࣷǎ tÑX┨ żඌỤµt£¬ĭϔ&36Ǯ4 Ș ȌՈϔₓ46Ǯ4 ň&ࢿΉǛĿ4Ⱥசɳ҉ 2.2 ̱ωĝσʗϏƉȼˍFĝ́Ƨ ᰻!ȕͧՈ๎ၠ ۔Ⱥசɳ҉Ụµt£Ո36Ǯ̓ &hTERT_¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈ3¦๎ Ⓒ̱ᯬ¾ඊྡྷɌ˝ϣ⑃ Ʈɍ̶ʳ Ɍ̩Ʈ3̶ṽƮ3 ƶ╓۔̓ ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈʐசɳ҉ඈ ɣඈȈ12Ǯ hTERT_ Ʈ3ൾ⏨Ʈz̶ᢖƮ(Ě1A)4ČႷৰ2ÏȒ๎ၠⒸ̱ᯬ ¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈ3¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈ ¾ඊྡྷ˝ợò¤ȷ 8 hό:ǀ͔˝ ඊྡྷɌɴţĄP ა[☝ͼȸࢿΉ๎ၠⒸ̱ᯬ¾ඊྡྷ˸^/ ႸՈt൨මඊྡྷʳ ඊྡྷ̶ɌřɶȸƮź3⑃̩ƮzG۔Ởẋ̓/ hTERT๎ၠⒸ̱ᯬ¾ඊྡྷ˸^ ¦๎ၠⒸ̱ᯬ¾ඊྡྷ˸ ॡźϣ⑃ ǾาºǺ␠[ᢆȓ4 ๎ၠⒸ̱ᯬ¾ඊྡྷ¿ţ ȯƅₓ ȀՈⒸՈඊྡྷϧò&2×106 L 14 ָǐ൪&15 µm ྡྷϚͱȯƅ^ 1.4.4 RT-PCR̼ϟ ỞẋTRIzolͩȴǚʇRNA ₋Ϭ௯ ՈʌɈȖ̩ȌĿ3ඃୖĿʐႸǺĿ ྡྷϚɬĐƅႮा͵ òᩥϟǎRNAȯₓ ÑǑḰơȌt᪙F֖᪸R ʐྡྷĢɃ͵ ඊྡྷzඊྡྷॅ᰻7Ⓒdzᢅ4ඊྡྷẢȉȀ̵̵ ̲ ẟᜐǑḰơ4PCRǑàǝâ94 ?ǜɳ5 min 95 ?ǜ ᢅĚ1B4ȕͧՈ๎ၠⒸ̱ᯬ¾ඊྡྷඓϕśඊྡྷÖℸǎȒdz ɳ30 s 54 ?Ễ̗36 s 72 ?łĤ30 s 36ɬƛǶɳȒ ᜬẂּàՈʃᩴĭ ܲᩨȕͧඊྡྷ&๎ၠⒸ̱ᯬ¾ඊྡྷ4 72 ?łĤ6 min4z4 ?[ljƌĭ4PCRɣPǑàₑ̩ 2.3 hTERTΆ9LJA̢ÝσʗϏƉȼˍFƏĝ2ê ẟᜐ3Ƶ4PCRĭǚ5 mLẟᜐϹ· Ñβ-actinň&ͱdž RT-PCR̼ϟº߾ ϹḰɏͩ·ȰhTERTȖüḰɏ๎ၠⒸ̱ +4Ϲ·ȒาGDSS000ωྺႮ¬tʻÖZı+ljƌĚʻ ᯬ¾ඊྡྷ48 hȒ Șº߾Ϧ2ǝ±ìǝr ᜬRNAᯬₓ àϬImage-Pro Plus 8.0ḳâ ȌhTERTՈǝr^β-actin Ι -Ϭ௯̲ඃ ̵̵òÖ̼ϟRNAńA260 nm A280 nm̠ Ȍ4 Ոȼ̵òȨ Șº߾A260 nm/280 nm=1.82.0 ᜬRNA൳ ǝrՈּȭ̜òɨȨ ẟᜐmRNAŎǎₓ òṇΙ PCRĭ̼ϟℸǎȘᜬhTERT_๎ၠⒸ̱ šĭÛ ᯬ¾ඊྡྷḰɏඈń750 bpdzᢅĽŎɳǝr ໐¦๎ၠⒸ̱ Ȗü šĭÛ ċɉ⑃ò ᯬ¾ඊྡྷࢿΉඈ3சɳ҉ඈ̼ϟƦᢅĽŎɳǝrᜬ\ hTERT Zä5’-CTGAAGTGTCACAGCCTGTTT-3' 1 1 1 bp hTERT mRNAՈᜬẂ ᢅĚ24 [ä5’-CACACATGCGTGAAACCTGTA-3' 1 1 1 bp 2.4 σʗϏƉȼˍF ű̢ɪȆîIJͻǂΛͻ ē β-actin Zä5’-TATCGGACGCCTGGTTAC-3' 151 bp ŵŋͬ)̼ ࢿΉȒ4ɬ ȭ+ඈᜄசljť൪4.0 mmol/L [ä5’-CTCAGCCTTGACTGTGCC-3' 1 51 bp சɳ҉ඈᜄச2226 mmol/LdzᢅºŋʌhTERT¦๎ h TERTୖ›ǑḰơ›4 ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈᜄசljť൪7.01 mmol/L3¦๎ၠⒸ / ᜄசǎᜄ±ྴ ̱ᯬ¾ඊྡྷࢿΉඈᜄசljť൪12.03 mmol/Lţƅ┑ĺ۔ၠⒸ̱ᯬ¾ඊྡྷࢿΉȒȈඈ̓๎ 1.4.5 ɣ hTERT¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈṇ¦๎ၠⒸ̱ᯬ¾ඊ۔ˈ¿̼ϟ ๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉȒ ȭȈඈ̓ˏ ɬǎrzɲ☝₋ᜄ -ϬᜄசÖർċͩϟǎाွᜄச ྡྷࢿΉඈՈᜄச┑ĺŰº(P < 0.05) ᢅᜬ14 ɣɬ2Ƶ4Ảන֕ϟᜄச6ɬ4z๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉȒ ࢿΉȒ6ɬ ^சɳ҉ඈɨṇ ¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿ Ȓඓွ'¬ ΉඈʐhTERT¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈՈᜄϚྴˏ⁍ٯ6ɬ ₋Ϭ7%ˈȌ˃ (5 mL/kg)ွဘͼȸ ǚᜄ ࡿȏ Ñ20 ?ljНᜄ± ƉǒELISA᪙F֖Ẕ ˈ¿ʺ¤ ྴှ҉ǃ࣏òλḿ ^¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿ ᜄϚྴˏˈ¿4 Ήඈּɨṇ hTERT¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈŰº۔ň᪸R ̼ϟȈඈ̓ 1.4.6 ๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉȒ҉ˊ̼ϟ ๎ၠⒸ̱ᯬ (P < 0.05) ᢅᜬ24 ¾ඊྡྷࢿΉȒৰ6ɬ ඓွ'¬ǚᜄȒ ẉợ-Ϭ)ʇͩ 2.5 σʗϏƉȼˍF ű̢îIJēȆŮDŨ)̼ ඈඋƅ]Ȑ࣏ˏྴ۔ှඈඋ Ñ40 g/L̶༞϶ Ėǎ ๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉȒ6ɬ Ȉඈ̓ྴ۔ȏ¬ĭ ǚȈඈ̠̓ ˏྴ ċ ₋ϬᆓƤஂö൦ᢈɏᄶ ᢆȓ̓ òՈǃǧ ྴˏඊྡྷūȏ ྴˏṽො̺ɳඊྡྷ$R ᗥẢනڷ ẋ̸ ๎¦Ո҉ˊǜĚ4 ₑ۸ū ྴˏඊྡྷᢅɅ 3ඈּɨṇ໐ᣄ hTERTˏྴ۔ 1.5 ƶϙʬ+ŷ/ ᢆȓȈඈᜄச¬ɍˈ¿ǜĚ zࢿΉ ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈՈྴˏඊྡྷǑàdzᢅºλḿ / ċᆓƤஂ_ ȀǀϘ ྴˏඊྡྷṇ̶ ࢿΉȒ6ɬ ^சɳ҉ඈɨṇ ᜄϚྴˏՈϧò ྴှ۔Ȓɣɬ̼ϟȈඈ̓ ö൦ɏᄶᢆȓ҉ˊǜĚ4 ¦๎ၠⒸ̱ᯬ¾ඊྡྷࢿΉඈʐhTERT¦๎ၠⒸ̱ᯬ¾ඊ 1.6 Ȍαǫʭ ǒɀϔǒţ₋ϬSPSS 15.0ḳâிඣ ྡྷࢿΉඈྴှ҉ǃ࣏òλḿ ɘ͢«hTERT_¦๎ၠⒸ̱ _ ẟᜐ Ȍ ϔȨ৪ȌǷɍ O ᩥₓᰈÑx±sᜬ߾ ඈ ᯬ¾ඊྡྷࢿΉඈŰº(P < 0.05) ᢅĚ34 ISSN 2095-4344 CN 21-1581/R CODEN: ZLKHAH 5829 Äņᇽ.